Weekly highlights, Nov 2 – Nov 8, 2026
This week brought a major regulatory milestone for psilocybin alongside preclinical studies that sharpen what is known about neural remodeling and reproducible behavioral effects. Other picks examine DMT biosynthesis, Colorado's access barriers, and the ethics of putting Indigenous rituals on reality television.
-
1
Usona submits psilocybin NDA for major depressive disorder as its regulatory race with Compass Pathways reaches a critical stage
Usona's filing puts a second psilocybin NDA before the FDA, with a potential decision in late 2026 or early 2027.
-
2
Psilocybin rewires neural circuits in mice through a pathway separable from psychedelic behavioral effects
Mouse experiments tied psilocybin's synaptic remodeling to cortical 5-HT2A receptors and separated it from head-twitch behavior.
-
3
Five mouse labs replicate psilocybin's acute fear and open-field effects, but persistent behavioral effects fail to replicate consistently
Five labs reproduced acute psilocybin effects in mice, but longer-term behavioral changes remained inconsistent.
-
4
Brasilianisches Forschungsteam rekonstruiert zweistufigen Biosyntheseweg zur DMT-Produktion in gentechnisch veränderten Bakterien
Engineered bacteria produced DMT through a reconstructed two-step pathway, demonstrating a new synthetic biology route.
-
5
Colorado’s regulated psilocybin program faces rising costs and barriers, prompting calls for safer, more accessible community care
High training, licensing, and facility costs are limiting access and sustainability in Colorado's regulated psilocybin system.
-
6
Heilige Medizin zur Primetime: Eine Kritik an „Surviving Amazonas“ und dem Umgang mit indigenen Ritualen im Reality-TV
The critique details consent, safety, coercion, and cultural appropriation concerns when Indigenous rituals become reality TV.